Have We Placed the Cart Before the Horse by Using Alpha-2A Agonists to
Treat Rejection Sensitivity Dysphoria in ADHD?

William   W.   Dodson; Edward   Justin   Modestino

doi:10.2174/0122115560297397240404071044

Keywords: Rejection sensitivity dysphoria, ADHD, alpha_-2a agonists.

[1]
Reimherr FW, Roesler M, Marchant BK, et al. Types of adult attention deficit/hyperactivity disorder: A replication analysis. J Clin Psychol  2002; 81(2): e1-7.

[2]
Wolraich ML, Chan E, Froehlich T, et al. ADHD diagnosis and treatment guidelines: A historical perspective. Pediatrics  2019; 144(4): e20191682.

[3]
Diagnostic and Statistical Manual of Mental Disorders.  (3rd ed.), Washington, DC, USA: American Psychiatric Association 1980.

[4]
Kooij JJS, Bijlenga D, Salerno L, et al. Updated European consensus statement on diagnosis and treatment of adult ADHD. Eur Psychiatry  2019; 56: 14-34.

[5]
Sibley M, Childress A.  Why we need US guidelines for adults with ADHD. 2022. Available from:
         https://ibcces.org/learning/why-we-need-u-s-guidelines-for-adults-with-adhd/

[6]
Stähle H. A historical perspective: Development of clonidine. Baillieres Clin Anaesthesiol  2000; 14: 237-46.

[7]
Cornish LA. Guanfacine hydrochloride: A centrally acting antihypertensive agent. Clin Pharm  1988; 7(3): 187-97.
 [PMID:  3281788]

[8]
Groom MJ, Cortese S. Current pharmacological treatments for ADHD. Curr Top Behav Neurosci  2022; 57: 19-50.
 [http://dx.doi.org/10.1007/7854_2022_330] [PMID:  35507282]

[9]
 Drug approval package.. Intuniv (guanfacine) NDA #022037. 2010. Available from:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022037_intuniv_toc.cfm

[10]
Fiks AG, Mayne SL, Song L, et al. Changing patterns of alpha agonist medication use in children and adolescents 2009-2011. J Child Adolesc Psychopharmacol  2015; 25(4): 362-7.
 [http://dx.doi.org/10.1089/cap.2014.0122] [PMID:  25919708]

[11]
Neuchat EE, Bocklud BE, Kingsley K, et al. The role of alpha-2 agonists for attention deficit hyperactivity disorder in children: A review. Neurol Int  2023; 15(2): 697-707.
 [http://dx.doi.org/10.3390/neurolint15020043] [PMID:  37218982]

Rights & Permissions Print Cite

Article Metrics

19

3

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0122115560297397240404071044	Print ISSN 2211-5560
Publisher Name Bentham Science Publisher	Online ISSN 2211-5579

Current Psychopharmacology

Have We Placed the Cart Before the Horse by Using Alpha-_2A Agonists to Treat Rejection Sensitivity Dysphoria in ADHD?

Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders

Current Psychopharmacology

Have We Placed the Cart Before the Horse by Using Alpha-2A Agonists to Treat Rejection Sensitivity Dysphoria in ADHD?

Call for Papers in Thematic Issues

Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders

Related Journals

Related Books

Have We Placed the Cart Before the Horse by Using Alpha-_2A Agonists to Treat Rejection Sensitivity Dysphoria in ADHD?